Research ArticleOriginal Article

Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cells

Arsen Osipov, Alex B. Blair, Juliane Liberto, Jianxin Wang, Keyu Li, Brian Herbst, Yao Xu, Shiqi Li, Nan Niu, Rufiaat Rashid, Ding Ding, Yanan Liu, Zaiqi Wang, Christopher L. Wolfgang, Richard A. Burkhart, Daniel Laheru and Lei Zheng
Cancer Biology & Medicine February 2021, 18 (1) 206-214; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0273

References

  1. 1.↵
    2. Rahib L,
    3. Smith BD,
    4. Aizenberg R,
    5. Rosenzweig AB,
    6. Fleshman JM,
    7. Matrisian LM.
    Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the united states. Cancer Res. 2014; 74: 2913–21.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    2. He J,
    3. Blair AB,
    4. Groot VP,
    5. Javed AA,
    6. Burkhart RA,
    7. Gemenetzis G, et al.
    Is a pathological complete response following neoadjuvant chemoradiation associated with prolonged survival in patients with pancreatic cancer? Ann Surg. 2018; 268: 1–8.
    OpenUrl
  3. 3.↵
    2. Hidalgo M.
    Pancreatic cancer. N Engl J Med. 2010; 362: 1605–17.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    2. Regine WF,
    3. Winter KA,
    4. Abrams R,
    5. Safran H,
    6. Hoffman JP,
    7. Konski A, et al.
    Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. intergroup/RTOG 9704 phase III trial. Ann Surg Oncol. 2011; 18: 1319–26.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.
    2. Hammel P,
    3. Huguet F,
    4. Van Laethem JL,
    5. Goldstein D,
    6. Glimelius B,
    7. Artru P, et al.
    Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib the LAP07 randomized clinical trial. J Am Med Assoc. 2016; 315: 1844–53.
    OpenUrlCrossRefPubMed
  6. 6.
    2. Neoptolemos JP,
    3. Stocken DD,
    4. Friess H,
    5. Bassi C,
    6. Dunn JA,
    7. Hickey H, et al.
    A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004; 350: 1200–10.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.
    2. Yovino S,
    3. Maidment BW,
    4. Herman JM,
    5. Pandya N,
    6. Goloubeva O,
    7. Wolfgang C, et al.
    Analysis of local control in patients receiving IMRT for resected pancreatic cancers. Int J Radiat Oncol Biol Phys. 2012; 83: 916–20.
    OpenUrlPubMed
  8. 8.
    2. Boyle J,
    3. Czito B,
    4. Willett C,
    5. Palta M.
    Adjuvant radiation therapy for pancreatic cancer: a review of the old and the new. J Gastrointest Oncol. 2015; 6: 436–44.
    OpenUrl
  9. 9.↵
    2. Klinkenbijl JH,
    3. Jeekel J,
    4. Sahmoud T,
    5. Van Pel R,
    6. Couvreur ML,
    7. Veenhof CH, et al.
    Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg. 1999; 230: 776–84.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    2. Orth M,
    3. Metzger P,
    4. Gerum S,
    5. Mayerle J,
    6. Schneider G,
    7. Belka C, et al.
    Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiat Oncol. 2019; 14: 141.
    OpenUrl
  11. 11.↵
    2. Yard BD,
    3. Adams DJ,
    4. Chie EK,
    5. Tamayo P,
    6. Battaglia JS,
    7. Gopal P, et al.
    A genetic basis for the variation in the vulnerability of cancer to DNA damage. Nat Commun. 2016; 7: 11428.
  12. 12.↵
    2. Lee Y,
    3. Auh SL,
    4. Wang Y,
    5. Burnette B,
    6. Wang Y,
    7. Meng Y, et al.
    Therapeutic effects of ablative radiation on local tumor require CD8 + T cells: changing strategies for cancer treatment. Blood. 2009; 114: 589–95.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    2. Morgan MA,
    3. Meirovitz A,
    4. Davis MA,
    5. Kollar LE,
    6. Hassan MC,
    7. Lawrence TS.
    Radiotherapy combined with gemcitabine and oxaliplatin in pancreatic cancer cells. Transl Oncol. 2008; 1: 36–43.
    OpenUrlCrossRefPubMed
  14. 14.↵
    2. Wild AT,
    3. Ye X,
    4. Ellsworth SG,
    5. Smith JA,
    6. Narang AK,
    7. Garg T, et al.
    The association between chemoradiation-related lymphopenia and clinical outcomes in patients with locally advanced pancreatic adenocarcinoma. Am J Clin Oncol Cancer Clin Trials. 2015; 38: 259–65.
    OpenUrl
  15. 15.↵
    2. Crocenzi T,
    3. Cottam B,
    4. Newell P,
    5. Wolf RF,
    6. Hansen PD,
    7. Hammill C, et al.
    A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma. J Immunother Cancer. 2016; 4: 45.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    2. Demaria S,
    3. Coleman CN,
    4. Formenti SC.
    Radiotherapy: changing the game in immunotherapy. Trends in Cancer. 2016; 2: 286–94.
    OpenUrl
  17. 17.
    2. Acharyya S,
    3. Oskarsson T,
    4. Vanharanta S,
    5. Malladi S,
    6. Kim J,
    7. Morris PG, et al.
    A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell. 2012; 150: 165–78.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.
    2. Ostrand-Rosenberg S,
    3. Horn LA,
    4. Ciavattone NG.
    Radiotherapy both promotes and inhibits myeloid-derived suppressor cell function: novel strategies for preventing the tumor-protective effects of radiotherapy. Front Oncol. 2019; 9: 215.
    OpenUrlPubMed
  19. 19.↵
    2. Gong J,
    3. Le TQ,
    4. Massarelli E,
    5. Hendifar AE,
    6. Tuli R.
    Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination. J Immunother Cancer. 2018; 6: 46.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    2. Osipov A,
    3. Saung MT,
    4. Zheng L,
    5. Murphy AG.
    Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape. J Immunother Cancer. 2019; 7: 224.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    2. Jiang H,
    3. Hegde S,
    4. Knolhoff BL,
    5. Zhu Y,
    6. Herndon JM,
    7. Meyer MA, et al.
    Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat Med. 2016; 22: 851–60.
    OpenUrlCrossRefPubMed
  22. 22.↵
    2. Tang KJ,
    3. Constanzo JD,
    4. Venkateswaran N,
    5. Melegari M,
    6. Ilcheva M,
    7. Morales JC, et al.
    Focal adhesion kinase regulates the DNA damage response and its inhibition radiosensitizes mutant KRAS lung cancer. Clin Cancer Res. 2016; 22: 5851–63.
    OpenUrlAbstract/FREE Full Text
  23. 23.
    2. Hou J,
    3. Zhou Z,
    4. Chen X,
    5. Zhao R,
    6. Yang Z,
    7. Wei N, et al.
    HER2 reduces breast cancer radiosensitivity by activating focal adhesion kinase in vitro and in vivo. Oncotarget. 2016; 7: 45186–98.
    OpenUrlCrossRef
  24. 24.↵
    2. Skinner HD,
    3. Giri U,
    4. Yang L,
    5. Woo SH,
    6. Story MD,
    7. Pickering CR, et al.
    Proteomic profiling identifies PTK2/FAK as a driver of radioresistance in HPV-negative head and neck cancer. Clin Cancer Res. 2016; 22: 4643–50.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    2. Cordes N,
    3. Frick S,
    4. Brunner TB,
    5. Pilarsky C,
    6. Grützmann R,
    7. Sipos B, et al.
    Human pancreatic tumor cells are sensitized to ionizing radiation by knockdown of caveolin-1. Oncogene. 2007; 26: 6851–62.
    OpenUrlCrossRefPubMed
  26. 26.↵
    2. Wang-Gillam A,
    3. Lockhart AC,
    4. Tan BR,
    5. Suresh R,
    6. Lim K-H,
    7. Ratner L, et al.
    Phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer. J Clin Oncol. 2018; 36: 2561.
    OpenUrl
  27. 27.↵
    2. Tiede S,
    3. Meyer-Schaller N,
    4. Kalathur RKR,
    5. Ivanek R,
    6. Fagiani E,
    7. Schmassmann P, et al.
    The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancer. Oncogenesis. 2018; 7: 73.
    OpenUrl
  28. 28.↵
    2. Hirt UA,
    3. Waizenegger IC,
    4. Schweifer N,
    5. Haslinger C,
    6. Gerlach D,
    7. Braunger J, et al.
    Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype. Oncogenesis. 2018; 7: 21.
    OpenUrl
  29. 29.↵
    2. Canel M,
    3. Taggart D,
    4. Sims AH,
    5. Lonergan DW,
    6. Waizenegger IC,
    7. Serrels A.
    T-cell co-stimulation in combination with targeting FAK drives enhanced anti-tumor immunity. Elife. 2020; 6: e48092.
  30. 30.↵
    2. de Jonge MJA,
    3. Steeghs N,
    4. Lolkema MP,
    5. Hotte SJ,
    6. Hirte HW,
    7. van der Biessen DAJ, et al.
    Phase I Study of BI 853520, an inhibitor of focal adhesion kinase, in patients with advanced or metastatic nonhematologic malignancies. Target Oncol. 2019; 14: 43–55.
    OpenUrl
  31. 31.↵
    2. Hingorani SR,
    3. Wang L,
    4. Multani AS,
    5. Combs C,
    6. Deramaudt TB,
    7. Hruban RH, et al.
    Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005; 7: 469–83.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    2. Foley K,
    3. Rucki AA,
    4. Xiao Q,
    5. Zhou D,
    6. Leubner A,
    7. Mo G, et al.
    Semaphorin 3D autocrine signaling mediates the metastatic role of annexin A2 in pancreatic cancer. Sci Signal. 2015; 8: ra77.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    2. Fujiwara K,
    3. Saung MT,
    4. Jing H,
    5. Herbst B,
    6. Zarecki M,
    7. Muth S, et al.
    Interrogating the immune-modulating roles of radiation therapy for a rational combination with immune-checkpoint inhibitors in treating pancreatic cancer. J Immunother cancer. 2020; 8: e000351.
  34. 34.↵
    2. Herman JM,
    3. Chang DT,
    4. Goodman KA,
    5. Dholakia AS,
    6. Raman SP,
    7. Hacker-Prietz A, et al.
    Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer. 2015; 121: 1128–37.
    OpenUrlCrossRefPubMed
  35. 35.↵
    2. Grapin M,
    3. Richard C,
    4. Limagne E,
    5. Boidot R,
    6. Morgand V,
    7. Bertaut A, et al.
    Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination. J Immunother Cancer. 2019; 7: 160.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    2. Vatner RE,
    3. Formenti SC.
    Myeloid-derived cells in tumors: effects of radiation. Semin Radiat Oncol. 2015; 25: 18–27.
    OpenUrlCrossRef
  37. 37.↵
    2. Wisdom AJ,
    3. Hong CS,
    4. Lin AJ,
    5. Xiang Y,
    6. Cooper DE,
    7. Zhang J, et al.
    Neutrophils promote tumor resistance to radiation therapy. Proc Natl Acad Sci U S A. 2019; 116: 18584–9.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    2. Serrels A,
    3. Lund T,
    4. Serrels B,
    5. Byron A,
    6. McPherson RC,
    7. Von Kriegsheim A, et al.
    Nuclear FAK controls chemokine transcription, tregs, and evasion of anti-tumor immunity. Cell. 2015; 163: 160–73.
    OpenUrlCrossRefPubMed
  39. 39.↵
    2. Lutz ER,
    3. Wu AA,
    4. Bigelow E,
    5. Sharma R,
    6. Mo G,
    7. Soares K, et al.
    Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol Res. 2014; 2: 616–31.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords